Irinotecan in Treating Patients With Recurrent Glioma
This study has been completed.
North Central Cancer Treatment Group
Information provided by:
National Cancer Institute (NCI)
First received: November 1, 1999
Last updated: January 27, 2009
Last verified: January 2009
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Primary Completion Date:||January 2009 (Final data collection date for primary outcome measure)|
Santisteban M, Buckner JC, Reid JM, Wu W, Scheithauer BW, Ames MM, Felten SJ, Nikcevich DA, Wiesenfeld M, Jaeckle KA, Galanis E. Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. J Neurooncol. 2008 Dec 10; [Epub ahead of print]
Laack N, Ballman KV, Brown PB, et al.: Whole-brain radiotherapy (WBRT) and high-dose methylprednisolone (HDMP) for elderly patients with primary central nervous system lymphoma (PCNSL): results of North Central Cancer Treatment Group (NCCTG) 96-72-51. [Abstract] Int J Radiat Oncol Biol Phys 60 (1 Suppl 1): A-1007, S260, 2004.